Skip to main content
. 2021 Aug 27;11:653162. doi: 10.3389/fonc.2021.653162

Table 10.

Key Papers Describing 2nd/3rd Line treatments in Metastatic Extra-Pulmonary LCNEC (most studies report outcomes for cohorts with combined SCNEC and LCNEC).

Study Study Design Patient population Total Patients Treatment Outcomes Other
Ando et al. (118) Retrospective review Advanced gastroenteropancreatic neuroendocrine carcinoma, first line therapy with platinum based chemotherapy 10 patients 2nd line amrubicin monotherapy

  • ORR 20%

  • Median OS 5.0 months
Hadoux et al. (119) Retrospective review Advanced poorly differentiated grade 3 neuroendocrine carcinoma, first line therapy with platinum based chemotherapy (combined all sites including 2 bronchus tumors, majority were GI primary sites) 20 patients (12 LCNEC, 7 SCNEC, 1 unknown) 2nd (N= 12) or 3rd line or greater (N=8) treatment with FOLFOX

  • 17 patients were evaluable, ORR 29%

  • Median OS 9.9 months
Nio et al. (120) Retrospective review GI extra-pulmonary neuroendocrine carcinoma, first line therapy with platinum based chemotherapy 13 patients 2nd line amrubicin monotherapy

  • ORR 38.5%

  • Median OS 7.1 months

GI, Gastrointestinal; OS, overall survival; LCNEC, Large cell neuroendocrine carcinoma; SCNEC, Small cell neuroendocrine carcinoma; ORR, overall response rate.